These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 21489836)

  • 1. Identification of a three-gene expression signature of early recurrence in non-muscle-invasive urothelial cell carcinoma of the bladder.
    Dubosq F; Ploussard G; Soliman H; Turpin E; Latil A; Desgrandchamps F; de The H; Mongiat-Artus P
    Urol Oncol; 2012; 30(6):833-40. PubMed ID: 21489836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of CD147, BIGH3 and Stathmin and their potential role as diagnostic marker in patients with urothelial carcinoma of the bladder.
    Bhagirath D; Abrol N; Khan R; Sharma M; Seth A; Sharma A
    Clin Chim Acta; 2012 Oct; 413(19-20):1641-6. PubMed ID: 22626996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does the expression of fascin-1 and tumor subclassification help to assess the risk of recurrence and progression in t1 urothelial urinary bladder carcinoma?
    Soukup V; Babjuk M; Dusková J; Pesl M; Szakáczová M; Zámecník L; Dvorácek J
    Urol Int; 2008; 80(4):413-8. PubMed ID: 18587253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stage, grade and behavior of bladder urothelial carcinoma defined by the microRNA expression profile.
    Dip N; Reis ST; Timoszczuk LS; Viana NI; Piantino CB; Morais DR; Moura CM; Abe DK; Silva IA; Srougi M; Dall'Oglio MF; Leite KR
    J Urol; 2012 Nov; 188(5):1951-6. PubMed ID: 22999546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer.
    Kim EJ; Lee YS; Kim YJ; Kim MJ; Ha YS; Jeong P; Lee OJ; Kim WJ
    Urology; 2010 Jun; 75(6):1516.e9-13. PubMed ID: 19913893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
    Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
    Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression profile of microrna-145 in urothelial bladder cancer.
    Dip N; Reis ST; Srougi M; Dall'Oglio MF; Leite KR
    Int Braz J Urol; 2013; 39(1):95-101; discussion 102. PubMed ID: 23489501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.
    Yan C; Kim YW; Ha YS; Kim IY; Kim YJ; Yun SJ; Moon SK; Bae SC; Kim WJ
    J Surg Oncol; 2012 Mar; 105(4):425-30. PubMed ID: 22311819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 9p21 index as estimated by dual-color fluorescence in situ hybridization is useful to predict urothelial carcinoma recurrence in bladder washing cytology.
    Kawauchi S; Sakai H; Ikemoto K; Eguchi S; Nakao M; Takihara H; Shimabukuro T; Furuya T; Oga A; Matsuyama H; Takahashi M; Sasaki K
    Hum Pathol; 2009 Dec; 40(12):1783-9. PubMed ID: 19733894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fascin is a predictor for invasiveness and recurrence of urothelial carcinoma of bladder.
    Bi J; Chen X; Zhang Y; Li B; Sun J; Shen H; Kong C
    Urol Oncol; 2012 Sep; 30(5):688-94. PubMed ID: 20888270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
    May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B
    Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer.
    Pignot G; Cizeron-Clairac G; Vacher S; Susini A; Tozlu S; Vieillefond A; Zerbib M; Lidereau R; Debre B; Amsellem-Ouazana D; Bieche I
    Int J Cancer; 2013 Jun; 132(11):2479-91. PubMed ID: 23169479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression analysis for the prediction of recurrence in patients with primary Ta urothelial cell carcinoma.
    Schultz IJ; Wester K; Straatman H; Kiemeney LA; Babjuk M; Mares J; Willems JL; Swinkels DW; Witjes JA; Malmström PU; de Kok JB
    Eur Urol; 2007 Feb; 51(2):416-22; discussion 422-3. PubMed ID: 16920253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative detection of cytokeratin 20 mRNA expression in bladder carcinoma by real-time reverse transcriptase-polymerase chain reaction.
    Christoph F; Müller M; Schostak M; Soong R; Tabiti K; Miller K
    Urology; 2004 Jul; 64(1):157-61. PubMed ID: 15245962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence.
    Schultz IJ; Kiemeney LA; Witjes JA; Schalken JA; Willems JL; Swinkels DW; de Kok JB
    Anticancer Res; 2003; 23(4):3327-31. PubMed ID: 12926071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression signature defined by FOXM1-CCNB1 activation predicts disease recurrence in non-muscle-invasive bladder cancer.
    Kim SK; Roh YG; Park K; Kang TH; Kim WJ; Lee JS; Leem SH; Chu IS
    Clin Cancer Res; 2014 Jun; 20(12):3233-43. PubMed ID: 24714775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
    Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
    Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative detection of cytokeratin 20 mRNA in urine samples as diagnostic tools for bladder cancer by real-time PCR.
    Guo B; Luo C; Xun C; Xie J; Wu X; Pu J
    Exp Oncol; 2009 Mar; 31(1):43-7. PubMed ID: 19300416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary cytokeratin 20 mRNA expression has the potential to predict recurrence in superficial transitional cell carcinoma of the bladder.
    Christoph F; Weikert S; Wolff I; Schostak M; Tabiti K; Müller M; Miller K; Schrader M
    Cancer Lett; 2007 Jan; 245(1-2):121-6. PubMed ID: 16473461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance in substaging ofT1 urinary bladder urothelial carcinoma on transurethral resection.
    Chang WC; Chang YH; Pan CC
    Am J Surg Pathol; 2012 Mar; 36(3):454-61. PubMed ID: 22261706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.